Neurotronic Reveals Innovative Clinical Results on Multi-Organ Denervation for Diabetes and Hypertension
Neurotronic's Groundbreaking Clinical Outcomes for Multi-Organ Denervation
Neurotronic, Inc. has recently taken a significant step forward in the treatment of chronic diseases such as type 2 diabetes mellitus (T2DM) and hypertension (HTN) by showcasing the first clinical outcomes of their innovative Neuviant™ Multi-Organ Denervation (MDN) therapy. These results were revealed during the Transcatheter Cardiovascular Therapeutics (TCT) 2025 conference held in San Francisco, CA, marking a pivotal moment in the fight against these widely prevalent conditions.
The Neuviant MDN procedure aims to tackle overactive sympathetic pathways, often associated with the body’s
Topics Other）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.